Ahmet Ataoglu1, Fatih Canan. 1. Department of Psychiatry, Faculty of Medicine, Duzce University, Duzce, Turkey.
Abstract
BACKGROUND: The relationship between major depression and increased platelet activity has been previously indicated by several studies. The aims of this study were to examine mean platelet volume (MPV), which is an indicator of platelet activity, in patients with depression and investigate whether escitalopram treatment would affect MPV. METHODS: Fifteen patients (11 women and 4 men) meeting the criteria for a current episode of major depressive disorder were recruited to the study and 17 physically and mentally healthy comparison subjects (11 women and 6 men). Mean platelet volume and platelet count of the controls and patients were measured upon entry to the study. After 8 weeks of open-label treatment with the selective serotonin reuptake inhibitor escitalopram (10-20 mg/d), the patients with depression were readmitted and the measurements were repeated. RESULTS: At baseline, in comparison with the control group, the group with depression exhibited greater platelet activity as detected by increased MPV. After escitalopram treatment, the patients with depression exhibited significant reduction in MPV. There was also a significant decline in platelet count. CONCLUSIONS: In this study, normalization of platelet activation is associated with escitalopram treatment for patients with depression. This finding may provide evidence for the use of escitalopram in patients with major depression and comorbid ischemic heart disease.
BACKGROUND: The relationship between major depression and increased platelet activity has been previously indicated by several studies. The aims of this study were to examine mean platelet volume (MPV), which is an indicator of platelet activity, in patients with depression and investigate whether escitalopram treatment would affect MPV. METHODS: Fifteen patients (11 women and 4 men) meeting the criteria for a current episode of major depressive disorder were recruited to the study and 17 physically and mentally healthy comparison subjects (11 women and 6 men). Mean platelet volume and platelet count of the controls and patients were measured upon entry to the study. After 8 weeks of open-label treatment with the selective serotonin reuptake inhibitor escitalopram (10-20 mg/d), the patients with depression were readmitted and the measurements were repeated. RESULTS: At baseline, in comparison with the control group, the group with depression exhibited greater platelet activity as detected by increased MPV. After escitalopram treatment, the patients with depression exhibited significant reduction in MPV. There was also a significant decline in platelet count. CONCLUSIONS: In this study, normalization of platelet activation is associated with escitalopram treatment for patients with depression. This finding may provide evidence for the use of escitalopram in patients with major depression and comorbid ischemic heart disease.
Authors: Hasan Mayda; Ahmet Ahsen; Erman Bağcioğlu; Ahmet Öztürk; Bülent Bahçeci; Etem Soyuçok; Erol Başpinar; Memnune Sena Ulu Journal: Noro Psikiyatr Ars Date: 2016-12-01 Impact factor: 1.339
Authors: Tam Truong Donnelly; Jassim Mohd Al Suwaidi; Awad Al-Qahtani; Nidal Asaad; Najlaa Abdul Qader; Rajvir Singh; Tak Shing Fung; Irem Mueed; Shima Sharara; Noha El Banna; Sarah Omar Journal: J Immigr Minor Health Date: 2015-08
Authors: M Krivosova; M Grendar; I Hrtanek; I Ondrejka; I Tonhajzerova; N Sekaninova; L Bona Olexova; D Mokra; J Mokry Journal: Physiol Res Date: 2020-12-31 Impact factor: 1.881